The stock of Globus Medical Inc (GMED) has gone down by -0.93% for the week, with a -1.66% drop in the past month and a 16.00% rise in the past quarter. The volatility ratio for the week is 2.63%, and the volatility levels for the past 30 days are 2.09% for GMED. The simple moving average for the last 20 days is -1.99% for GMED stock, with a simple moving average of 20.55% for the last 200 days.
Is It Worth Investing in Globus Medical Inc (NYSE: GMED) Right Now?
The price-to-earnings ratio for Globus Medical Inc (NYSE: GMED) is 123.61x, which is above its average ratio. Moreover, the 36-month beta value for GMED is 1.19. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 5 as “overweight,” 5 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for GMED is 112.93M and currently, short sellers hold a 2.16% of that float. On December 20, 2024, GMED’s average trading volume was 874.56K shares.
GMED) stock’s latest price update
The stock price of Globus Medical Inc (NYSE: GMED) has surged by 0.20 when compared to previous closing price of 81.78, but the company has seen a -0.93% decline in its stock price over the last five trading sessions. zacks.com reported 2024-12-19 that The Healthcare sector sees volume growth and improved occupancy while battling rising medical costs and regulatory uncertainty.
Analysts’ Opinion of GMED
Many brokerage firms have already submitted their reports for GMED stocks, with Morgan Stanley repeating the rating for GMED by listing it as a “Overweight.” The predicted price for GMED in the upcoming period, according to Morgan Stanley is $100 based on the research report published on December 02, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see GMED reach a price target of $78, previously predicting the price at $60. The rating they have provided for GMED stocks is “Overweight” according to the report published on August 07th, 2024.
Piper Sandler gave a rating of “Overweight” to GMED, setting the target price at $80 in the report published on May 20th of the current year.
GMED Trading at 3.11% from the 50-Day Moving Average
After a stumble in the market that brought GMED to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.05% of loss for the given period.
Volatility was left at 2.09%, however, over the last 30 days, the volatility rate increased by 2.63%, as shares sank -1.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.33% upper at present.
During the last 5 trading sessions, GMED fell by -0.93%, which changed the moving average for the period of 200-days by +50.38% in comparison to the 20-day moving average, which settled at $83.60. In addition, Globus Medical Inc saw 53.76% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GMED starting from Huller Kelly, who sale 2,500 shares at the price of $87.00 back on Dec 02 ’24. After this action, Huller Kelly now owns 0 shares of Globus Medical Inc, valued at $217,502 using the latest closing price.
Huller Kelly, the Officer of Globus Medical Inc, proposed sale 2,500 shares at $86.95 during a trade that took place back on Dec 02 ’24, which means that Huller Kelly is holding shares at $217,364 based on the most recent closing price.
Stock Fundamentals for GMED
Current profitability levels for the company are sitting at:
- 0.07 for the present operating margin
- 0.55 for the gross margin
The net margin for Globus Medical Inc stands at 0.04. The total capital return value is set at 0.04. Equity return is now at value 2.22, with 1.75 for asset returns.
Based on Globus Medical Inc (GMED), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 0.95. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is 21.68.
Currently, EBITDA for the company is 310.13 million with net debt to EBITDA at -0.17. When we switch over and look at the enterprise to sales, we see a ratio of 4.47. The receivables turnover for the company is 4.21for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.51.
Conclusion
To wrap up, the performance of Globus Medical Inc (GMED) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
